Approved for use through 10/3 2002.OMB
U. S. Palent and Trademark Office: U.S. DEPARTMENT OF CO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OME

Complete if Known Substitute for form 1449A/PTO 10/050,552 Application Number INFORMATION DISCLOSURE January 18, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Ronaldo A. Nagem Art Unit 1641 (use as many sheets as necessary) Not Yet Assigned **Examiner Name** 2 1 of LUD-5722/10111925

Attorney Docket Number

U.S. PATENT DOCUMENTS Pages, Columns, Lines, **Document Number Publication Date** Name of Patentee or Applicant Where Relevant Examiner Cite of Cited Document MM-DD-YYYY Number-Kind Code² (If known) Passages or Relevat Initials* No.1 5,835,382 Wilson et al. AA 11-10-1998 40 3 0 50015000 07-19-2000 AB 6,090,609 Luo et al. AC 6,242,201 06-05-2001 Lane et al. AD 6,251,620 06-26-2001 Hatada et al. 6,273,598 08-14-2001 ΑE Keck et al. 10-16-2001 6,303,287 ΑF Kim et al. AG

		FOREI	GN PATENT	DOCUMENTS	15.	
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pagas, Columns, Lines, Where Relevant	
		Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)		Applicant of Cited Document	Passages or Relevant Figures Appear	T
we	ВА	WO 00/24758	05-04-2000	Ludwig Institute for Cancer Research		

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.1	. I itam /haak maaayisa iskesal asaan aum-a-ika matalaa atab data aaaa/-b(!)		
R	CA	Table of Contents – special emphasis on COLIGAN et al., Current Protocols in Immunology, 1(2), Chapter 5 (1991)		
3	СВ	COOKSON, W., "The alliance of genes and environment in asthma and allergy", Nature, 402s: B5-B11 (2000)		
K	CC	DUMOUTIER, L. et al., "Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-9", J. Immunol. 164: 1814-1819 (2000)		
Me	CD	DUMOUTIER, L. et al., "Human interleukin-10-related T cell-derived inducible factor: Molecular cloning and functional characterization as an hepatocyte-stimulating factor", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 97: 10144-10149 (2000)		
M	CE	DUMOUTIER, L. et al., "IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes", Genes and Immunity 1: 488-494 (2000)		
NP	CF 	ESNOUF, R., "An extensively modified version of MolScript that includes greatly enhanced coloring capabilities", <i>J. Mol. Graph.</i> 15: 133-138 (1997)		
Ne	CG	FITZLOFF, J., "The Impact of Biotechnology on Analytical Methodology", Biotechnology and Pharmacy – Chapter 5: 97-115, (edited by Pezzuto et al.) (1993)		
he	CH	KOTENKO, S., et al., "Identification and functional characterization of a second chain of the interleukin-10 receptor complex", EMBO J. 16(19): 5894-5903 (1997)		
NO	CI	KOTENKO, S., et al., "Identification of the Functional Interleukin-22 (IL-22) Receptor Complex", J. Biol. Chem. 276: 2725-2732 (2001)		
we	CJ	KRAULIS, P., "MolScript: a program to produce both detailed and schematic plots of protein structures", J. Appl. Cryst. 24: 946-950 (1991)		

Nather 7/7/04





TECH CENTER 1600/2900

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

S	ubstitute for form 1449B/PT	o		Complete if K		
				Application Number	10/050,552	
1	NFORMATIO	N DIS	CLOSURE	Filing Date	January 18, 2002	
(STATEMENT	BY A	PPLICANT	First Named Inventor	Ronaldo Nagem 2002	
/				Group Art Unit	1641 CENTER 1600/a	
법_	(use as many s	heels as n ——	ecessary)	Examiner Name	Not Yet Assigned	
et	2	of	2	Attorney Docket Number	LUD-5722/10111925	

P		
Me	CK	LASKOWSKI, R., et al., "Procheck: a program to check the sterochemical quality of protein structures", J. Appl. Cryst. 26: 283-291 (1993)
M	†CL	LEVITT, R., et al., "IL-9 pathway in asthma: New therapeutic targets for allergic inflammatory disorders", J. Allergy Clin. Immunol. 103: 485-491 (1999)
NR	СМ	MCLANE, M., et al., "Interleukin-9 Promotes Allergen-Induced Eosinophilic Inflammation and Airway Hyperresponsiveness in Transgenic Mice", Am. J. Respir. Cell Mol. Biol. 19: 713-720 (1998)
Me	CN	MORGAN, B., et al., "Approaches to the Discovery of Non-Peptide Ligands for Peptide Receptors and Peptidases", (edited by Vinick) In: Ann. Rep. Med. Chem. 24: 243-252 (1989)
Me	СО	POLIKARPOV, I., et al., "Set-up and Experimental Parameters of the Protein Crystallography Beamline at the Brazilian National Synchrotron Laboratory", J. Synchrotron Rad. 5: 72-76 (1998)
Me	СР	POLIKARPOV, I., et al., "The protein crystallography beamline at LNLS, the Brazilian National Synchrotron Light Source", Nucl. Instrum. And Methods, A405: 159-164 (1998)
M	CQ	SIMON, R., et al., "Peptoids: A modular approach to drug discovery", Proc. Natl. Acad. Sci. U.S. A. 89: 9367-9371 (1992)
Ne	CR	TEMANN, U, et al., "Expression of Interleukin 9 in the Lungs of Transgenic Mice Causes Airway Inflammation, Mast Cell Hyperplasia, and Bronchial Hyperresponsiveness", J. Exp. Med. 188(7): 1307-1320 (1998)
Nl	CS	XIE, M., et al., "Interleukin (IL-22), a Novel Human Cytokine That Signals through the Interferon Receptor-related Proteins CRF2-4 and IL-22R", J. Biol. Chem. 275(40): 31335-31339 (2000)
WP	СТ	ZDANOV, A., et al., "Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon γ", Structure 3: 591-601 (1995)

Examiner	W W		Date	
	4	7/1/64	Date ,	<i>(</i>
Signature	1 //avee	711107	Considered	'
			Donaidered	<u></u> _

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.